Amber Toombs
Family · Jonesboro, ARNPI 1497910624
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,391 of the $11,655 with a category attached, or 89.2%. Sanofi-aventis U.S. LLC accounts for 71.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $9,356 and has fallen 97.5% since, to $231 in 2025. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $135.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$8K
- Novo Nordisk$2K
- Lilly USA, LLC$345
- AstraZeneca$176
- Sequel Med Tech, LLC$108
- Boehringer Ingelheim$104
- plus $296 from 11 others
What the payments were for
- Speaking & faculty fees$10,39189%
- Food & beverage$1,25211%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 25 | $8,384 |
| Novo Nordisk | 3 | $2,242 |
| Lilly USA, LLC | 17 | $345 |
| AstraZeneca | 12 | $176 |
| Sequel Med Tech, LLC | 5 | $108 |
| Boehringer Ingelheim | 7 | $104 |
| Medtronic | 2 | $61 |
| Bayer | 3 | $52 |
| Dexcom, Inc. | 3 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| BETA Bionics, Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$4,270
- TOUJEO$2,684
- RYBELSUS$2,242
How this compares
$11,655 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 339 | $366,904 |
| MounjaroTirzepatide | 191 | $205,158 |
| JardianceEmpagliflozin | 206 | $141,552 |
| Tresiba Flextouch U-200Insulin Degludec | 94 | $107,781 |
| TrulicityDulaglutide | 88 | $89,494 |
| FarxigaDapagliflozin Propanediol | 68 | $53,175 |
| Tresiba Flextouch U-100Insulin Degludec | 81 | $50,837 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $47,723 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $39,069 |
| JanuviaSitagliptin Phosphate | 46 | $33,636 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 22 | $25,760 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $24,574 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $23,025 |
| Humulin R U-500Insulin Regular, Human | 14 | $21,067 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $15,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $2,242 | $404,994392 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin N | $345 | $298,528303 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $104 | $156,866230 claims |
| AstraZenecaFarxiga | $176 | $53,17568 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $8,384 | $13,09211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Jonesboro
- Stefanie BrackinJonesboro$51K
- Jessica MatthewsJonesboro$19K
- Kimberly DanielsJonesboro$14K
- Kimberly RoddyJonesboro$12K
- Christopher JordanJonesboro$12K
- Tracy ThompsonJonesboro$11K
- Ashley SheltonJonesboro$10K
- Steven VanderbiltJonesboro$10K
- Erika VanceJonesboro$10K
- Ashley DentonJonesboro$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.